Épisodes

  • The AI Economic Doomsday Report That Shook Wall Street

    The AI Economic Doomsday Report That Shook Wall Street
    Feb 27 2026
    A viral blog post by a relatively unknown research firm sent the stock market on a wild ride this week. The post by Citrini Research tapped into a new strain of fears about artificial intelligence, painting a dark portrait of a future in which technological change leads to mass white collar unemployment. WSJ’s David Uberti explains why Wall Street is jumpy about the prospects for AI. Ryan Knutson hosts. Further Listening: - The Era of AI Layoffs Has Begun- AI Is Coming for Entry-Level Jobs And listen to Camp Swamp Road, full playlist here.Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Voir plus Voir moins
    20 min
  • How One Company Is Navigating a New Era of Tariff Uncertainty

    How One Company Is Navigating a New Era of Tariff Uncertainty
    Feb 26 2026
    Newell Brands, the Atlanta-based maker of dozens of household brands including Rubbermaid, Coleman and Yankee Candle, paid more than $170 million in tariffs last year. Newell’s CEO Chris Peterson tells Jessica Mendoza that those tariffs hurt business and the company is considering requesting a refund. He also talks about plans to bring more manufacturing to America. One of its brands, Sharpie, is now almost completely made in the United States. But making that happen wasn’t easy. Further Listening: Trump's Tariffs Are Illegal. He's Got a Plan B. How Tariffs Could End Italian Pasta in the U.S. How to Make a $12.98 T-Shirt... in the U.S. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Voir plus Voir moins
    23 min
  • Inside Mexico's Decision to Take Down a Drug Lord

    Inside Mexico's Decision to Take Down a Drug Lord
    Feb 25 2026
    After Mexican authorities killed El Mencho, the country’s most powerful drug lord, his cartel responded with violence across the country. The operation came amid pressure from the U.S. government on Mexico's President Claudia Sheinbaum. WSJ’s José De Córdoba explains the power struggle that will ensue among the cartels and what it means for the global drug trade. Ryan Knutson hosts. Further Listening: - Mexico's New Cocaine Kingpin is Cashing In- Drug Cartels' New Weapon: Chinese Money Launderers Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Voir plus Voir moins
    19 min
  • A Chinese Manufacturer Came to Ohio. Its Rivals Are Struggling to Compete.

    A Chinese Manufacturer Came to Ohio. Its Rivals Are Struggling to Compete.
    Feb 24 2026
    President Trump has spent much of the past year trying to pump up international investment in U.S. factories. He's promised to bring back jobs that have moved overseas. WSJ’s Gavin Bade investigates a Chinese automotive glass plant in the Ohio heartland and explores the risks when America’s biggest rival sets up shop. Jessica Mendoza hosts. Further Listening: - Trump's Tariffs Are Illegal. He's Got a Plan B. - How Tariffs Could End Italian Pasta in the U.S. - The Tariff Trade Off: Jobs vs. Higher Prices Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Voir plus Voir moins
    18 min
  • Anthropic’s Pentagon Problems

    Anthropic’s Pentagon Problems
    Feb 23 2026
    Anthropic is feuding with the U.S. military, despite their massive $200 million contract. The company says that its AI model, Claude, cannot be used for weapons development or surveillance. The Pentagon is pushing back against those limitations. WSJ's Amrith Ramkumar joins Jessica Mendoza to explain why the Department of Defense is now threatening to label Anthropic a supply chain risk. Further Listening: - AI Bots Have Social Media Now. It Got Weird Fast. - Vibe Coding Could Change Everything - Her Client Was Deepfaked. She Says xAI Is to Blame. Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Voir plus Voir moins
    19 min
  • Trump's Tariffs Are Illegal. He's Got a Plan B.

    Trump's Tariffs Are Illegal. He's Got a Plan B.
    Feb 20 2026
    In a 6-3 decision, the Supreme Court ruled that President Trump’s global tariffs are illegal. It is the first time the Supreme Court has definitively struck down one of Trump’s second-term policies, saying the president went too far in enacting his most sweeping tariffs without clear authorization from Congress. WSJ’s Gavin Bade unpacks the ruling and discusses Trump’s next steps. Ryan Knutson hosts. Further Listening: - Trump's Tariffs Force a New Era in Global Trade - How Tariffs Could End Italian Pasta in the U.S. - The Tariff Trade Off: Jobs vs. Higher Prices Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Voir plus Voir moins
    20 min
  • In A Landmark Trial, Zuckerberg Takes the Stand

    In A Landmark Trial, Zuckerberg Takes the Stand
    Feb 19 2026
    Yesterday, Meta CEO Mark Zuckerberg testified in a first-of-its-kind trial with one central question: Are social media platforms causing mental health disorders among young people? The plaintiff argues that platforms like Instagram are designed to keep children addicted, potentially bypassing long-standing legal shields that have protected tech companies in the past. WSJ’s Meghan Bobrowsky takes us inside the courtroom for Mark Zuckerberg’s testimony and explains why this trial could impact thousands of other cases. Ryan Knutson hosts. Further Listening: - The Battle Within Meta Over Chatbot Safety - “The Facebook Files’ from The Journal. Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Voir plus Voir moins
    22 min
  • The Flu Shot Drama at the FDA

    The Flu Shot Drama at the FDA
    Feb 18 2026
    The Food and Drug Administration agreed to begin a review of biotech company Moderna’s application to make a new seasonal flu shot available. The decision comes after the FDA initially refused to review the company's application. It's a back and forth that reveals increased turmoil within the agency. WSJ’s Liz Essley Whyte takes us inside the FDA’s unexpected reversals and explores what’s next for the mRNA flu vaccine. Jessica Mendoza hosts. Further Listening: - The FDA Commissioner on Vaccines and Public Trust - Breakfast Battle: The Cereal Industry vs MAHA Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Voir plus Voir moins
    20 min